SANUWAVE Health, Inc. (SNWV) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite challenges like net income decline and forecasting difficulties, the company shows strong revenue growth (42% YoY) and improved gross margins. The Q&A reveals plans to enhance production and marketing, with promising debt refinancing. The guidance aligns with strong growth, and operational strategies seem on track, suggesting positive sentiment.
Key Financial Performance
Revenue $10.2 million for Q2 2025, an increase of 42% compared to $7.2 million for the same period in 2024. This growth was attributed to continued momentum in the commercial strategy and growing demand for UltraMIST.
Gross Margin 78.3% for Q2 2025, up 510 basis points from 73.2% in Q2 2024. The improvement was due to reduced costs on UltraMIST system production and a strategic focus on pricing for UltraMIST systems and applicators.
Operating Income $1.9 million for Q2 2025, slightly down by $0.1 million compared to the same period last year. The decrease was due to increased operating expenses.
Operating Expenses $6.1 million for Q2 2025, up from $3.2 million in Q2 2024, an increase of $2.9 million. This was driven by a $1.1 million increase in noncash stock-based compensation expense and the absence of a $579,000 historical accrual release that occurred in Q2 2024.
Net Income $1.1 million for Q2 2025, down from $6.6 million in Q2 2024, a decrease of $5.5 million. The decline was primarily due to lower non-cash and infrequent items, including the absence of a $5.3 million one-time noncash gain related to legacy debt payoff in Q2 2024 and a $2.7 million year-over-year variance in the change in fair value of derivative liabilities.
EBITDA $3.2 million for Q2 2025. Adjusted EBITDA was $3.4 million, an improvement of $1.9 million compared to $1.5 million in Q2 2024.
Applicator Revenue $6.4 million for Q2 2025, representing 63% of overall revenues. This was a 37% increase compared to the same quarter last year and over 10% sequential growth from the previous quarter.
UltraMIST Systems Sold 116 systems in Q2 2025, a 61% increase compared to the same period last year and an 18% increase from Q1 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
UltraMIST systems: Sold 116 units in Q2, a 61% increase year-over-year and 18% increase from Q1. Total systems in the field reached 1,261, with 38% sold in the last 12 months.
New applicator design: Commercial production of a new, more manufacturable applicator design is on track for Q4 2025. This design will increase capacity and reduce production costs.
Market adoption: Increased inbound inquiries in several markets, indicating crossing an adoption threshold for UltraMIST. Plans to expand awareness and launch the first outbound marketing campaign in October 2025.
Sales and commercial operations: Expanded sales team to 12 national territories and added a full-time national and key accounts manager. Enhanced commercial operations team with new leadership.
Operational efficiencies: Gross margins improved to 78.3%, up 510 basis points year-over-year, driven by reduced production costs and strategic pricing.
Strategic shifts: Significant changes in sales leadership, sales force, and commercial strategy. Focus on internal system upgrades, lead and sales management, and reimbursement support.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Sales Leadership and Strategy Changes: The company underwent significant changes in sales leadership, sales force, commercial operations, and strategy, described as 'max disruption.' This could pose risks to operational stability and execution during the transition period.
Dependence on Key Customers: Customer concentration remains a concern, with one customer accounting for over 5% of revenues. This reliance on key customers could impact financial stability if these customers reduce or cease purchases.
Production Costs and Margins: Gross margins slightly declined from Q1 due to engineering costs for a new applicator production design. While this is expected to improve efficiency in the future, it poses short-term financial risks.
Operating Expenses: Operating expenses increased significantly by $2.9 million year-over-year, driven by noncash stock-based compensation and the absence of prior year accrual releases. This could pressure profitability if not managed effectively.
Net Income Decline: Net income decreased by $5.5 million year-over-year, primarily due to lower noncash and infrequent items. This decline could affect investor confidence and financial flexibility.
Forecasting Challenges: The company faces challenges in forecasting large customer sales, which could lead to revenue volatility and impact financial planning.
Facility Constraints: The company has outgrown its current headquarters, particularly warehouse and shipping facilities, which could disrupt operations until the move to a new facility is completed.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Q3 2025: The company is guiding to $12 million to $12.7 million in Q3 revenues. This guidance is conservative due to the tough comparison with Q3 2024, which had an 89% year-on-year growth rate driven by a large one-time sale. The company is not including potential large customer sales in this guidance.
Annual Guidance: The annual guidance remains unchanged, though specific figures were not provided in the transcript.
Production and Cost Efficiency: The company plans to commence commercial production of a new, more manufacturable applicator design in Q4 2025. This design is expected to provide ample applicator capacity and reduce consumables production costs.
Marketing and Sales Expansion: The company is preparing for its first-ever concerted outbound marketing campaign, expected to launch in October 2025. Additionally, the company has fully staffed its 12 national sales territories and added a full-time national and key accounts manager.
Market Adoption and Awareness: The company is focusing on expanding awareness and adoption of its UltraMIST product, leveraging key users to provide social proof and credibility. Promising increases in inbound inquiries have been observed in certain markets.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you give us a sense as to how the enhanced production process for applicators might impact gross margin?
A:The new applicator design aims to increase production capacity and reduce costs, potentially improving margins by 350-400 basis points. However, the impact will be gradual due to existing inventory, with significant effects expected by early 2026.
Q:Do you envision needing to build out the 13 reps, or is the current number sufficient?
A:The current number of 13 reps is sufficient for national coverage, but there may be a few additions or sector-specific hires. The company is also considering regional managers as the next step.
Q:Where are you focusing your marketing efforts for UltraMIST in the U.S.?
A:The marketing program is tailored to specific wound types, patient types, and user types. Efforts are focused on mobile wound care, nursing homes, skilled nursing facilities, hospitals, podiatry, and wound care centers. The goal is to build trust and achieve critical mass in key regions.
Q:Any update on the senior secured debt that's coming due?
A:The company has received attractive term sheets and chosen one lender. They are in the process of closing the deal, which is expected to offer significant improvements over the current terms. Specific details and the counterparty were not disclosed.
Q:Can you discuss the progress in 'elephant hunting' with the new team?
A:The company has been added to the approved vendor list of a major hospital chain and is targeting large accounts with hundreds of locations. Progress is in early stages, with the new key accounts rep hired in July. Results are expected as momentum builds.
Q:Can you talk about the value and scope of the company's 140 patents?
A:The company holds a large patent portfolio related to shockwave and ultrasound technologies, providing core operational protection. Some patents have been monetized, such as a $2.5 million option deal for vascular condition patents. The company is exploring further opportunities for licensing or monetization.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the senior secured debt, including the counterparty and exact terms. Additionally, they were vague about the progress and potential outcomes of the 'elephant hunting' initiative, citing early stages and competitive reasons for withholding details.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Abiomed energy
Albert Hanser
Applicator revenue
Bauser ROTH
CEO Chairman
CEO sale
CFO Secretary
Capital LLC
Capital Partners
Chairman CFO
Division Conference
ET day
Frank CEO
Hanser Unidentified
Instructions pleasure
Kyle Royal
LLC Kyle
LLC Research
Partners LLC
UltraMIST system
account
adoption
amount
applicator
basis point
construction
decrease
disclosure
disruption
income period
market
meeting
month income
month period
noncash gain
ops
SNWV Transcript
SANUWAVE Health, Inc. (SNWV) Q1 2026 Earnings Call Transcript
Unknown5-13
Despite a slight revenue increase and optimistic guidance, the company's financial health is concerning due to increased operating expenses, a decline in gross margin, and extended sales cycles. The Q&A reveals confidence in future growth but lacks specifics on product advancements and market expansion. The transition to wholesale pricing and sales tax exposure add further risk. Overall, the financial metrics and uncertainties suggest a negative stock price movement in the short term.
SANUWAVE Health, Inc. (SNWV) Q4 2025 Earnings Call Transcript
Positive3-27
The earnings call highlights a strong financial performance with a 25% revenue increase, improved gross margins, and a shift from net loss to net income. The positive cash flow indicates solid financial health. Despite the absence of strategic and operational updates, the financial metrics suggest a positive outlook. However, the lack of strategic guidance and acknowledgment of risks tempers the sentiment slightly. The overall impact is likely positive, given the financial turnaround and margin improvements.
SANUWAVE Health, Inc. (SNWV) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call summary indicates a focus on cost efficiency, marketing expansion, and a conservative revenue guidance due to past anomalies. The Q&A section reveals positive sentiment towards sales strategies and potential growth, despite some uncertainties in adoption timelines. Key factors like improved financial footing and inbound interest from distributors suggest a positive outlook. However, the lack of international expansion and cautious revenue guidance temper expectations. Overall, the sentiment is positive, with a potential stock price increase of 2% to 8% over the next two weeks.
SANUWAVE Health, Inc. (SNWV) Q3 2025 Earnings Call Transcript
Unknown10-6
The earnings call reveals several negative aspects, including a miss on Q3 revenue guidance, market uncertainty impacting growth, and challenges in forecasting. Despite some positive developments like a record September revenue and improved sales pipeline, the downward adjustment of annual revenue guidance and regulatory risks weigh heavily. The Q&A section reflects cautious optimism but lacks specific details, and the refusal to provide detailed guidance further dampens sentiment. These factors suggest a likely stock price decline in the range of -2% to -8%.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
